Zosano Pharma Corp (ZSAN) [Rocket]

In millions, except per share items	Mar-31-22	Dec-31-21	Sep-30-21	Mar-31-21	Dec-31-20	Sep-30-20	Jun-30-20	Jun-05-20
	10-Q	10-K	10-Q	10-Q	10-K	10-Q	10-Q	8-K
Revenues				0.5	0.2	4.9	0.0
Revenue growth						-25.7%
Cost of goods sold				0.3	0.2	7.7	0.0
Gross profit				0.1	0.1	0.0	0.0
Gross margin				30.9%	23.7%	-56.1%
Selling, general and administrative [+]				10.9	11.2	11.7	12.0
General and administrative				10.9	11.2	11.7	12.0
Research and development				21.4	21.6	21.9	22.6
EBITDA [+]				-30.5	-31.3	-32.4	-33.8
EBITDA growth				-14.3%	-14.2%	-12.7%	-6.6%
EBITDA margin				-6332.2%	-13987.5%	-664.1%
Depreciation and amortization				1.7	1.4	1.2	0.8
EBIT [+]				-32.2	-32.8	-33.6	-34.6
EBIT growth				-11.3%	-11.9%	-12.1%	-6.2%
EBIT margin				-6682.6%	-14624.1%	-680.6%
Interest expense, net [+]				0.6	0.7	0.7	0.8
Interest expense				0.6	0.7	0.7	0.8
Interest income				0.0	0.0	0.0	0.1
Other income (expense), net [+]				0.0	0.1	0.1	0.0
Other				0.0	0.1	0.1	0.0
Pre-tax income				-32.8	-33.4	-34.2	-35.4
Income taxes				0.0	0.0	0.0	0.0
Tax rate				0.0%	0.0%	0.0%	0.0%
Net income				-32.8	-33.4	-34.2	-35.4
Net margin				-6809.5%	-14896.9%	-693.7%

Basic EPS [+]				($0.64)	($0.56)	($0.74)	($1.13)
Growth				-61.8%	-76.4%	-73.3%	-61.8%
Diluted EPS [+]				($0.64)	($0.56)	($0.74)	($1.13)
Growth				-61.8%	-76.4%	-73.3%	-61.8%

Shares outstanding (basic) [+]				50.9	59.2	46.4	31.4
Growth				133.2%	275.8%	230.4%	149.5%
Shares outstanding (diluted) [+]				50.9	59.2	46.4	31.4
Growth				133.2%	275.8%	230.4%	149.5%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.